ATE383154T1 - Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivaten und radiotherapie - Google Patents

Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivaten und radiotherapie

Info

Publication number
ATE383154T1
ATE383154T1 AT03714888T AT03714888T ATE383154T1 AT E383154 T1 ATE383154 T1 AT E383154T1 AT 03714888 T AT03714888 T AT 03714888T AT 03714888 T AT03714888 T AT 03714888T AT E383154 T1 ATE383154 T1 AT E383154T1
Authority
AT
Austria
Prior art keywords
radiotherapy
distamycin
tumor therapy
therapy based
acryloyl derivatives
Prior art date
Application number
AT03714888T
Other languages
English (en)
Inventor
Maria Geroni
Jennifer Tursi
Camilla Fowst
Original Assignee
Nerviano Medical Sciences Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nerviano Medical Sciences Srl filed Critical Nerviano Medical Sciences Srl
Application granted granted Critical
Publication of ATE383154T1 publication Critical patent/ATE383154T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
AT03714888T 2002-04-02 2003-03-17 Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivaten und radiotherapie ATE383154T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02076240 2002-04-02

Publications (1)

Publication Number Publication Date
ATE383154T1 true ATE383154T1 (de) 2008-01-15

Family

ID=28459529

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03714888T ATE383154T1 (de) 2002-04-02 2003-03-17 Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivaten und radiotherapie

Country Status (19)

Country Link
US (1) US20110166077A9 (de)
EP (1) EP1490053B1 (de)
JP (1) JP2005527552A (de)
KR (1) KR100968657B1 (de)
CN (1) CN1302777C (de)
AT (1) ATE383154T1 (de)
AU (1) AU2003219102B2 (de)
BR (1) BR0308976A (de)
CA (1) CA2481005C (de)
DE (1) DE60318561T2 (de)
ES (1) ES2299692T3 (de)
IL (2) IL164356A0 (de)
MX (1) MXPA04009542A (de)
NO (1) NO20044709L (de)
NZ (1) NZ535700A (de)
PL (1) PL373998A1 (de)
RU (1) RU2314807C2 (de)
WO (1) WO2003082267A1 (de)
ZA (1) ZA200407948B (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0015446D0 (en) * 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl distamycin derivates,taxanes and/or antimetabolites
MXPA05009851A (es) * 2003-03-18 2005-12-06 Pharmacia Italia Spa Como radiosensibilizador en combinacion con terapia con radiacion contra tumores.
AU2006233856A1 (en) * 2005-04-08 2006-10-19 Nerviano Medical Sciences S.R.L. Antitumor combination comprising substituted acryloyl distamycin derivatives and antibodies inhibiting growth factors or their receptors
RU2478374C1 (ru) * 2012-02-06 2013-04-10 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Минздравсоцразвития России Способ внутриполостной терапии при лечении больных с метастазами рака во влагалище

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990012321A1 (en) * 1989-03-31 1990-10-18 The Cancer Institute Board Halogenated dna ligand radiosensitisers for cancer therapy
JPH0925268A (ja) * 1995-07-12 1997-01-28 Taiho Yakuhin Kogyo Kk ２−ニトロイミダゾール誘導体
GB9615692D0 (en) * 1996-07-25 1996-09-04 Pharmacia Spa Acryloyl substituted distamycin derivatives, process for preparing them, and their use as antitumor and antiviral agents
US6331286B1 (en) * 1998-12-21 2001-12-18 Photogen, Inc. Methods for high energy phototherapeutics
JP2002515511A (ja) * 1998-05-15 2002-05-28 イムクローン システムズ インコーポレイティド 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療
US6498181B1 (en) * 1999-01-06 2002-12-24 Maxim Pharmaceuticals Synergistic tumorcidal response induced by histamine
US6576759B2 (en) * 1999-02-10 2003-06-10 Pangene Corporation Antisense inhibition of RAD51
GB0011059D0 (en) * 2000-05-08 2000-06-28 Pharmacia & Upjohn Spa Use of substituted acryloyl distamycin derivatives in the treatment of tumours associated with high levels of glutathione
GB0015447D0 (en) * 2000-06-23 2000-08-16 Pharmacia & Upjohn Spa Combined therapy against tumors comprising substituted acryloyl derivates and alkylating agents
US6576612B1 (en) * 2000-10-02 2003-06-10 Pharmacia Italia S.P.A. Antitumor therapy comprising distamycin derivatives

Also Published As

Publication number Publication date
IL164356A (en) 2010-11-30
CA2481005C (en) 2009-06-09
WO2003082267A1 (en) 2003-10-09
JP2005527552A (ja) 2005-09-15
ES2299692T3 (es) 2008-06-01
PL373998A1 (en) 2005-09-19
RU2314807C2 (ru) 2008-01-20
ZA200407948B (en) 2006-08-30
MXPA04009542A (es) 2005-01-25
NZ535700A (en) 2007-06-29
KR100968657B1 (ko) 2010-07-06
HK1079116A1 (en) 2006-03-31
KR20040101379A (ko) 2004-12-02
DE60318561D1 (de) 2008-02-21
CN1302777C (zh) 2007-03-07
US20050143315A1 (en) 2005-06-30
NO20044709L (no) 2004-12-30
CN1649583A (zh) 2005-08-03
IL164356A0 (en) 2005-12-18
US20110166077A9 (en) 2011-07-07
BR0308976A (pt) 2005-01-11
AU2003219102B2 (en) 2008-05-08
DE60318561T2 (de) 2009-01-08
EP1490053B1 (de) 2008-01-09
RU2004131860A (ru) 2005-04-10
EP1490053A1 (de) 2004-12-29
CA2481005A1 (en) 2003-10-09
AU2003219102A1 (en) 2003-10-13

Similar Documents

Publication Publication Date Title
DE60037394D1 (de) VERWENDUNG VON p53 INHIBITOREN ZUR BEHANDLUNG VON NEBENERSCHEINUNGEN BEI DER KREBSTHERAPIE
DK1558616T4 (da) Meso-substituerede porphyriner
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
DK1853250T3 (da) Kombinationer og måder til indgivelse af terapeutiske midler og kombinationsterapi
ATE408601T1 (de) Fredericamycin-derivate
DE602005026105D1 (de) Verwendung von agonisten und antagonisten von interleukin-33 (il-33)
NO20054988D0 (no) Preparater og metoder for behandling av cancer
DE60229922D1 (de) Kombinationen, ein antidiarrhoikum und epothilon oder ein epothilonderivat enthaltend
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
NO20064794L (no) Anvendelse av anti-alfa5beta1-antistoffer for inhibering av kreftcelleproliferasjon
DE60230194D1 (de) Therapeutische verwendung von mitgliedern der n,n-dicylcohexyl-2-hydroxy-7,7-dimethylbicycloä2.2.1ühept-1-ylmethanesulphonamide-familie
ATE317849T1 (de) 5-hydroxysapogenin derivate mit aktivität gegen demenz
ATE427773T1 (de) Verwendung von n-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-a1,3,4- xadiazol-2-yluphenyl)pyridin-3- sulphonamid in der tumortherapie
ATE383154T1 (de) Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivaten und radiotherapie
NO20053903D0 (no) Nukleotidlipidesterderivater.
PL1651774T3 (pl) Zastosowanie palimorfizmów ludzkiego OATP-C związanych z wpływem na farmakokinetykę statyn u ludzi leczonych statynami
TR200102557T2 (tr) Tiazonlindolinon bileşikleri.
HRP20080597T3 (en) Cancer combination therapy comprising azd2171 and zd1839
DE60326931D1 (de) In kanzerösen mammazellen differentiell exprimierte genprodukte und ihre verwendungsverfahren
ATE415165T1 (de) Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivate und antimetabolische mitteln
TR200302193T4 (tr) Kombinasyon kemoterapisi.
MXPA05002477A (es) Asialo-interferones y el tratamiento de cancer de higado.
ATE256682T1 (de) Sigma-2 rezeptoren als biomarkierer der tumorzellenproliferation
ATE271878T1 (de) Verwendung von protein h als zytostattischer wirkstoff
DK1463541T3 (da) Biomaterialer baseret på hyaluronsyrebenzylester til anti-angiogen terapi i behandling af tumorer

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1490053

Country of ref document: EP

REN Ceased due to non-payment of the annual fee